Endometrium at Menopause: The Pathologist's View.

These polyps show similar glands [ Figure 7a ] but have smooth muscle in their stroma, usually as irregular bundles and strands in proximity to thick-walled vessels [ Figure 7b ].[ 9 ] Although smooth muscle is present, the glands are invested by stroma, sometimes resembling a focus of adenomyosis. These polyps usually have proliferative/hyperplastic or functional gland pattern. (a) Adenomyomatous polyp showing dilated and tubular endometrial glands with surrounding smooth muscle (HE stain, ×5). (b) Smooth muscle (green arrows)-rich stroma in an adenomyomatous polyp (HE stain, ×10)

Focally evident cystically dilated glands with intervening tubular proliferative phase glands are characteristics of disordered proliferative endometrium [ Figure 3 ]. Disordered proliferation is a pattern that is neither normal nor diffusely hyperplastic, resulting from sustained estrogenic stimulation.[ 4 ] Disordered proliferative endometrium characterized by few dilated and cystic (red arrow) glands amid tubular proliferative phase glands (blue arrow) (HE stain, ×10)

Endometrial hyperplasia is defined as a proliferation of glands of irregular size and shape with an associated increase in the gland/stroma ratio compared with proliferative endometrium. In 1994 and 2003, the World Health Organization (WHO) and the International Society of Gynecologic Pathologists promoted a system for endometrial hyperplasia classification, which subdivided hyperplasia into four groups according to their nuclear alterations (atypia vs. without atypia) and degree of architectural crowding defined by the extent of back-to-back glandular crowding (complex vs. simple). Although this approach to endometrial hyperplasia diagnosis was better, subsequent studies showed poor-to-moderate interobserver agreement (kappa = 0.337–0.60).[ 10 11 ] Accordingly, the 2014 WHO Classification of Female Genital Tumours (4 th edition) simplified the four-tier system into two groups based on the presence of atypia while ignoring the extent of glandular crowding.[ 12 ] Endometrial hyperplasia (WHO 2020) is now subdivided into two broad categories: Endometrial hyperplasia without atypia Endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia (EAH/EIN). Endometrial hyperplasia without atypia Endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia (EAH/EIN). This is characterized by an increased gland/stroma ratio and a variety of abnormal architectural patterns. Glands typically vary in size and shape. Dilatation and outpouching of glandular epithelium characterize the architectural abnormalities [ Figure 8a ]. In other instances, the glands are only minimally dilated but focally crowded. Increased gland-to-stroma ratio is a characteristic of this entity [ Figure 8b ]. The atypical glands must be distributed throughout the tissue sampled. (a) Endometrial hyperplasia without atypia showing a “Swiss-cheese” appearance. An increased gland-to-stroma ratio is seen, with dilated and branching glands (HE stain, ×10). (b) Cystic glands seen throughout the field (HE stain, ×20). (c) Normal proliferative endometrium for comparison (HE stain, ×5) This term now also includes the earlier entity of complex hyperplasia which is characterized by increasing glandular architectural complexity, but without nuclear atypia and a lesser risk of progression to malignancy. Progression to endometrial carcinoma occurs in 1%–3% of women with hyperplasia without atypia.[ 8 ] EAH/EIN is characterized by a crowded glandular architecture distinct from surrounding endometrium or entrapped glands, with atypical nuclear features distinct from the background endometrium or entrapped normal glands [ Figure 9 ].[ 8 ] The abnormal focus should have a linear dimension more than 1 mm for making a diagnosis on endometrial biopsies and would translate to half the size of a low-power (×10) magnification.[ 13 ] Endometrial hyperplasia with atypia (endometrioid intraepithelial neoplasia) showing closely packed, back-to-back glands with scant intervening stroma. The cells show atypical and rounded nuclei with prominent nucleoli (red arrow) (HE stain, ×20) Initially termed “endometrial intraepithelial neoplasia” (2000), the term was modified to “endometrioid” in the WHO 2014 to better reflect its specific association with endometrioid carcinoma (EC).[ 13 ] The European Working Group (EWG) had also developed a classification for endometrial proliferative lesions. According to the EWG classification, simple and complex hyperplasia without atypia was referred to as “hyperplasia,” while atypical hyperplasia and well-differentiated ECs were combined into a single category designated “endometrial neoplasia.”[ 13 ] One-quarter to one-third of EAH/EIN will have cancer at immediate hysterectomy or during the 1 st year of follow-up.[ 8 ] EC is characterized by increasing glandular complexity with glandular, papillary, and solid architecture of endometrioid glands. On biopsies, EC is differentiated from EIN by (1) stromal invasion defined by a confluent glandular, cribriform, or maze-like pattern, (2) a desmoplastic stroma, or (3) a complex papillary/villoglandular architecture [ Figure 10 ].[ 8 ] A size criterion has also been described, the confluent growth being extensive enough to involve at least one-half of a low-power (×4) field, a distance of 2.0 mm [ Figure 10a ]. Brisk mitotic activity is generally seen in the atypical glands [ Figure 10b ].[ 14 ] In resection specimens, invasion into the underlying myometrium is usually seen [ Figure 11 ]. (a) Endometrial biopsy showing confluent glandular proliferation. This confluent growth measured more than 2 mm (HE stain, ×0.5). (b) Atypical glands showing brisk mitoses (blue arrows) (HE stain, ×20) (a) Gross photograph of a hysterectomy showing an endometrial growth on the right lateral wall (red arrow). (b) Endometrioid carcinoma showing myometrial invasion (yellow arrow) (HE stain, ×5). (c) Squamous morules (black arrow) in a case of endometrial carcinoma are metaplastic and not considered while grading the tumor (HE stain, ×10). (d) Neoplastic endometrial glands invading the myometrium (blue arrow) (HE stain, ×10) In the recent WHO classification, a two-tier grading system has been recommended, where grades 1 and 2 are labeled as low grade while grade 3 is high grade.[ 8 ] Four molecular subtypes with distinct prognoses are described: (1) POLE ultramutated, (2) mismatch repair–deficient, (3) p53 mutant [ Figure 12 ], and (4) no specific molecular profile EC [ Table 1 ].[ 8 ] A limited panel of immunohistochemistry and POLE mutation analysis is useful in assessing prognosis in the grade 3 ECs. Molecular signatures also show carcinosarcoma to be an aggressive variant of endometrial carcinoma arising from epithelial–mesenchymal transition, rather than a mixed epithelial and mesenchymal neoplasm, and are included as a type of endometrial carcinoma in the new WHO 2020 [ Figure 13 ].[ 8 ] (a) Photomicrograph of a case of endometrioid carcinoma showing high-grade features, characterized by solid nests (blue arrow) with surrounding desmoplastic stroma (HE stain, ×10). (b) On immunohistochemistry, this tumor showed a diffuse, strong nuclear positivity for ER (IHC, ×20 for ER). (c) p53 also showed strong nuclear positivity in more than 75% of cells, consistent with mutant phenotype (IHC, ×10 for p53). (d) p16 showed a patchy positivity (IHC, ×10 for p16). This immunohistochemical pattern is diagnostic of an endometrioid carcinoma, p53-mutant molecular subtype Molecular subtypes of endometrioid carcinoma EC: Endometrioid carcinoma, NSMP: No-specific molecular profile, BMI: Body mass index, IHC: Immunohistochemistry, MSI: Microsatellite instability, MMR: mismatch repair, GC: giant cells, TILs: tumor-infiltrating lymphocytes, NGS: next-generation sequencing, CTNNB-1: Catenin beta 1 gene (a) Gross photograph of a hysterectomy showing a fleshy polypoidal growth entirely filling the cavity (blue arrow). (b) Photomicrograph from the same case showing carcinomatous (blue arrow) and sarcomatous elements (red arrow), infiltrating the myometrium indicating a carcinosarcoma (HE stain, ×10). (c) The tumor shows marked nuclear pleomorphism (blue arrows). Abnormal and brisk mitoses are seen in the tumor (yellow arrows) (HE stain, ×20) Serous carcinoma (10%) [ Figure 14 ], clear cell carcinoma (<10%), undifferentiated and dedifferentiated carcinomas, mixed carcinoma, carcinosarcoma, rarer types such as mesonephric adenocarcinoma, squamous cell carcinoma, and primary gastric type mucinous carcinoma are also encountered in the postmenopausal endometrium. Immunohistochemistry with a panel of antibodies is helpful in typing.[ 8 ] (a) Serous carcinoma characterized by a papillary growth pattern with fibrovascular cores (blue arrow) and hierarchical, complex branching (yellow arrow) (HE stain, ×2). (b) Myometrial invasion (arrow) in a case of serous carcinoma (HE stain, ×5). (c) The papillae are lined by markedly atypical cells showing hyperchromatic and pleomorphic nuclei with multiple mitoses, including atypical ones (arrows) (HE stain, ×40) To summarize, the endometrium at menopause may be inactive but is home to a myriad of neoplastic and nonneoplastic pathologies. Therefore, a careful, thorough histopathological examination in correlation with clinical evaluation is essential for proper diagnosis and management of these conditions. Nil. There are no conflicts of interest.

The histological appearance of the postmenopausal endometrium is variable. The endometrium is usually thin, and this is best appreciated in hysterectomy or endometrial resection specimens [ Figure 5a ]. The glands vary from small, widely spaced atrophic tubules to cystically dilated glands throughout, an appearance called cystic atrophy or senile cystic atrophy [ Figure 5b ]. A mixture of small tubules and cystically dilated glands may occur. An absence of proliferative and mitotic activity [ Figure 4b ] distinguishes it from proliferative endometrium.[ 1 ] This cystic change may not be observed in endometrial biopsies because tissue fragmentation during the procedure disrupts the glands, imparting the characteristic appearance described above. (a) Atrophic endometrium from a hysterectomy showing thinned out endometrium with atrophic, tubular glands (blue arrow) and a fibrous stroma (red arrow) (HE stain, ×10). (b) A case of senile cystic atrophy with cystic glands (yellow arrow) lined by cuboidal cells (HE stain, ×10) The stroma may be densely cellular and composed of ovoid-to-spindle–shaped cells [ Figure 4b ] or more fibrous appearance than in premenopausal women [ Figure 5a ]. This fibrous change may be the direct cause of the cystic change because of blockage of the glands [ Figure 5b ]. Postmenopausal endometria are similar to those of atrophic endometrium due to other causes, such as exogenous hormones, premature ovarian failure, or radiotherapy.

Endometrium undergoes cyclical modifications under hormonal influence during reproductive life. While the endometrium normally atrophies and remains inactive after menopause, a plethora of disorders affect the endometrium at this stage. In this pictorial review, we highlight these morphologic aspects.